Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100087
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2004-12-22
Brief Title:
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSightTM Ocular Brachytherapy System
Sponsor:
Theragenics Corporation
Organization:
Theragenics Corporation
Study Overview
Official Title:
A Safety and Feasibility Study of the TheraSightTM Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration
Status:
UNKNOWN
Status Verified Date:
2005-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will investigate the safety and feasibility of using the TheraSightTM Brachytherapy System for treatment of wet age-related macular degeneration AMD
Detailed Description:
This is a multi-center randomized study of three doses of radiation assigned 111 delivered by the TheraSightTM Brachytherapy System in participants with choroidal neovascularization CNV secondary to wet exudative AMD Each participant receives a single dose of radiation delivered by one-time only brachytherapy Participants are followed for three years after the radiation treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None